Table 1.

Treatment	N - response	PR	P - PR	N-EFS	mEFS	P-EFS gain
all	58	7		61	0.172
XRT-Primary	7	4	0.002	7	0.326	0.017
XRT-MET	2	0	0.775	2	0.036	0.099
Bevacizumab	12	2	0.438	13	0.172	0.374
Irinotecan	13	2	0.486	13	0.172	0.985
Valproic acid	11	2	0.388	13	0.156	0.984
Nimotuzumab	13	1	0.517	13	0.186	0.494
Oral Etoposide	10	1	0.662	12	0.151	0.706
IV etoposide	2	1	0.225	2	0.326	0.046
Temozolomide	8	1	0.661	8	0.255	0.037
Cetuximab	5	1	0.481	5	0.211	0.693
Rapamycin	3	1	0.32	3	0.096	0.668
CCNU	2	0	0.775	2	0.096	0.633
Cis-retinoic acid	2	0	0.775	2	0.033	0.056
Cereport	2	0	0.775	2	0.151	0.633
Carboplatin	2	0	0.775	2	0.151	0.633
Vincristine	2	0	0.775	2	0.364	0.042
Temsirolimus	2	0	0.775	2	0.214	0.627
Cisplatin	2	1	0.225	2	0.326	0.046

Responses and median progression free survival of patients treated for recurrent diffuse intrinsic pontine glioma with various treatment combinations. There were no CRs. The number of patients evaluable for response (n-Response) and the number of partial responses (PR) are shown in the first two columns follows by the P-values of Chi square tests comparing those responses to those of patients receiving other recurrence treatments. No P-value was defined as significant as this is only an observational study. The number of patients included in the event free survival calculation (n-EFS), the median EFS as Kaplan Meier Estimate, are shown in the next two columns. The last column shows the P-value of a Kruskal Wallis test comparing EFS gain of patients treated with the drug to those treated with other drugs as a measure if improved EFS is a relevant finding.